{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stem+Cell+Transfusion",
    "query": {
      "intervention": "Stem Cell Transfusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 64,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stem+Cell+Transfusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T09:12:11.610Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03432364",
      "title": "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transfusion Dependent Beta-thalassemia"
      ],
      "interventions": [
        {
          "name": "ST-400 Investigational product",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-03-29",
      "completion_date": "2022-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Oakland, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432364"
    },
    {
      "nct_id": "NCT00849745",
      "title": "Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Nonmyeloablative allogeneic stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 4,
      "start_date": "2003-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-06-23",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849745"
    },
    {
      "nct_id": "NCT04592705",
      "title": "Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Therapeutic plasma exchange",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Larkin Community Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-09-11",
      "completion_date": "2021-08-30",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "South Miami, Florida",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04592705"
    },
    {
      "nct_id": "NCT02986698",
      "title": "In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alpha Thalassemia Major",
        "Hemoglobinopathy; With Thalassemia",
        "Hemoglobinopathies",
        "Fetal Anemia",
        "Fetal Hydrops",
        "Alpha; Thalassemia",
        "Thalassemia Major",
        "Thalassemia Alpha",
        "A-Thalassemia"
      ],
      "interventions": [
        {
          "name": "in utero hematopoietic stem cell transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Weeks",
        "maximum_age": "26 Weeks",
        "sex": "ALL",
        "summary": "18 Weeks to 26 Weeks"
      },
      "enrollment_count": 6,
      "start_date": "2017-10-05",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02986698"
    },
    {
      "nct_id": "NCT00176852",
      "title": "Stem Cell Transplant for Hemoglobinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Severe Congenital Neutropenia",
        "Diamond-Blackfan Anemia",
        "Shwachman-Diamond Syndrome"
      ],
      "interventions": [
        {
          "name": "Busulfan, Fludarabine, ATG, TLI",
          "type": "DRUG"
        },
        {
          "name": "Busulfan, Cyclophosphamide, ATG, GCSF",
          "type": "DRUG"
        },
        {
          "name": "Campath, Fludarabine, Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 22,
      "start_date": "2002-06",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176852"
    },
    {
      "nct_id": "NCT01773395",
      "title": "GVAX vs. Placebo for MDS/AML After Allo HSCT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "GVAX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2013-01-08",
      "completion_date": "2021-11-24",
      "has_results": true,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773395"
    },
    {
      "nct_id": "NCT05444894",
      "title": "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transfusion Dependent Beta Thalassemia",
        "Hemoglobinopathies",
        "Thalassemia Major",
        "Thalassemia Intermedia"
      ],
      "interventions": [
        {
          "name": "EDIT-301",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Editas Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-04-29",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 7,
      "location_summary": "Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05444894"
    },
    {
      "nct_id": "NCT06078696",
      "title": "Siplizumab for Sickle Cell Disease Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "Siplizumab",
          "type": "DRUG"
        },
        {
          "name": "Exchange Transfusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Body Irradiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Rituximab or Biosimilar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2023-09-28",
      "completion_date": "2025-12-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06078696"
    },
    {
      "nct_id": "NCT01490723",
      "title": "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "111In Ibritumomab",
          "type": "DRUG"
        },
        {
          "name": "Planar Scintigraphy Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "90Y IbritumomabTiuxetan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-01",
      "completion_date": "2019-04-24",
      "has_results": true,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01490723"
    },
    {
      "nct_id": "NCT01369160",
      "title": "Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Quality of Life measures",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "23 Years",
        "sex": "ALL",
        "summary": "3 Years to 23 Years"
      },
      "enrollment_count": 33,
      "start_date": "2005-05",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-09-10T09:12:11.610Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369160"
    }
  ]
}